

In the Claims:

Claims 1-26 (Cancelled)

27. (Currently Amended): An isolated polypeptide comprising a member selected from the group consisting of

- (a) ~~an amino acid sequence matching SEQ ID NO:2 or SEQ ID NO:4 and~~
- (b) ~~an immunogenic polypeptide comprising a fragment sequence of at least 15 amino acids that matches an aligned contiguous segment of SEQ ID NO:2, wherein the immunogenic fragment consists of at least 15 contiguous amino acids of SEQ ID NO:2 or SEQ ID NO:4;~~

wherein the isolated polypeptide, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response to a polypeptide consisting having the sequence of SEQ ID NO:2 or SEQ ID NO:4.

28. (Cancelled)

29. (Previously Added): The isolated polypeptide of claim 27, wherein the polypeptide is according to (a).

Claims 30-31 (Cancelled)

32. (Previously Added): The isolated polypeptide of claim 27, wherein the polypeptide is according to (b).

33. (Cancelled)

34. (Previously Added): The isolated polypeptide of claim 27, wherein the immunogenic fragment of (b) comprises at least 20 amino acids.

35. (Previously Added): The isolated polypeptide of claim 27, wherein the isolated polypeptide consists of SEQ ID NO:2 or SEQ ID NO:4.

Claims 36-37 (Cancelled)

38. (Currently Amended): A fusion protein comprising the isolated polypeptide of Claim 27
21.

Claims 39-42 (Cancelled)

B³
43. (Currently Amended): An immunogenic composition ~~A vaccine~~ comprising the polypeptide of Claim 27 and a pharmaceutically acceptable carrier.

44. (Currently Amended): The immunogenic composition ~~vaccine~~ of Claim 43, wherein the immunogenic composition ~~vaccine~~ comprises at least one other *Moraxella catarrhalis* antigen.

Claims 45-49 (Cancelled)